GlobeStar Therapeutics Corporation (GSTC)
| Market Cap | 248.22K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -919.30K |
| Shares Out | 1.24B |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,661,536 |
| Average Volume | 2,020,530 |
| Open | 0.0002 |
| Previous Close | 0.0002 |
| Day's Range | 0.0002 - 0.0002 |
| 52-Week Range | 0.0001 - 0.0012 |
| Beta | 2.05 |
| RSI | 45.13 |
| Earnings Date | Jun 27, 2025 |
About GlobeStar Therapeutics
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington. [Read more]
Financial Performance
Financial StatementsNews
Globestar Therapeutics Update on Project Amethyst(TM) and Recent Financials
RICHLAND, WA / ACCESSWIRE / March 28, 2024 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) (GSTC), is a clinical stage pharmaceutical company focused on advancing new therapies for Multiple Scler...
GlobeStar Therapeutics Enters Into Definitive Agreement With Advanced Innovative Partners To Develop Clinical Studies and Strategies for Multiple Sclerosis Treatment
RICHLAND, WA / ACCESSWIRE / November 2, 2023 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC), (GSTC), a clinical-stage pharmaceutical company focused on advancing new therapies for Multiple Scler...
Globestar Therapeutics Enters into Definitive Agreement with SMI Healthcare to Manage Clinical Trial, Regulatory Filings, Manufacturing and Sales in MEA Region for Multiple Sclerosis Treatment
RICHLAND, WA / ACCESSWIRE / September 28, 2023 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) (GSTC), a clinical-stage pharmaceutical company focused on advancing new therapies for Multiple Scle...
Globestar Therapeutics Enters into MOU with Advanced Innovative Partners to Develop Clinical Studies for Multiple Sclerosis Treatment
RICHLAND, WA and PALM BEACH, FL / ACCESSWIRE / June 14, 2023 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) (GSTC), a clinical-stage pharmaceutical company focused on advancing new therapies for...
GlobeStar Therapeutics Corporation Update on Recent Activity
RICHLAND, WA / ACCESSWIRE / August 2, 2022 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC), headquartered in Richland, Washington, is a clinical stage pharmaceutical company introducing a patente...
CORRECTING and REPLACING GlobeStar Therapeutics Corporation Awards New York Bay Capital, LLC Investment Banking Contract
Agency selected because of performance history and a deep understanding of the company's healthcare, technology, and lifestyle spaces. RICHLAND, WA / ACCESSWIRE / March 1, 2022 / GlobeStar Therapeutic...
GlobeStar Therapeutics Corporation Awards New York Bay Capital, LLC Investment Banking Contract
Agency selected because of performance history and a deep understanding of the company's healthcare, technology, and lifestyle spaces. RICHLAND, WA / ACCESSWIRE / March 1, 2022 / GlobeStar Therapeutic...
GlobeStar Therapeutics Corporation Addresses the Potential Link Between Neurodegenerative Disease and Parkinson's Disease
Company will work with its team of professionals to determine if our proprietary medical treatment will help Parkinson's patients as well. RICHLAND, WA / ACCESSWIRE / February 4, 2022 / GlobeStar Ther...
GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets
Company will move from the Pink tier to QB tier effective immediately while retaining the same ticker symbol. RICHLAND, WA / ACCESSWIRE / October 11, 2021 / GlobeStar Therapeutics Corporation (OTCQB:G...
GlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial.
Company has made progress with a major medical center in the Northeast and identified a path forward for this pharmaceutical. RICHLAND, WA / ACCESSWIRE / October 4, 2021 / GlobeStar Therapeutics Corpo...
GlobeStar Therapeutics Corporation Files New 8K Statement Focused On Progress, Market Acceptance, And A Potential Game-Changing Drug For Multiple Sclerosis
Company has made significant progress and identified a path forward for this pharmaceutical. RICHLAND, WA / ACCESSWIRE / September 20, 2021 / GlobeStar Therapeutics Corporation (OTCBB: GSTC) has filed...
GlobeStar Therapeutics Corporation Unveils New Corporate Website and Branding Campaign
New website goes live in tandem with a major branding campaign to be found in USA Today. RICHLAND, WA / ACCESSWIRE / July 21, 2021 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) is launching its...
GlobeStar Therapeutics Corporation To Be Seen In The Washington Football Team Yearbook All Season
RICHLAND, WA / ACCESSWIRE / July 15, 2021 / GlobeStar Therapeutics Corporation has partnered with the Washington Football Team Yearbook producers for inclusion in their annual book. GlobeStar Therapeu...
AngioSoma, Inc. Is Officially GlobeStar Therapeutics Corporation.
FINRA Approval for the AngioSoma name change is effective immediately. RICHLAND, WA / ACCESSWIRE / July 6, 2021 / AngioSoma, Inc. (OTC PINK:SOAN) is now officially GlobeStar Therapeutics Corporation (...